



CIN-L24230GJ1995PLC025878

Cadila
Healthcare Limited**Regd. Office :**

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

September 16, 2014

Bombay Stock Exchange Limited

1st Floor, P.J. Towers
Dalal Street
MUMBAI - 400 001

Kind Attn.: Mr. Sanjay Golecha
Mr. Gopalkrishnan

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra - (East)
Mumbai - 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited

Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad - 380 015

Re.: Press Release.

Dear Sir / Madam

We enclose herewith a copy of press release dated September 16, 2014 under the title
"Zydus receives tentative approval for Glipizide ER tablets" to be released in the News
Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the
investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED
UPEN H. SHAH**COMPANY SECRETARY**

Encl.: As above.



Press Release

Press Release

Press Release

Press Release

Press Release

Press Release

Zydus receives tentative approval for Glipizide ER tablets

Ahmedabad, 16 September 2014

Zydis Cadila has received tentative approval from the USFDA to market Glipizide Extended-release tablets in the strengths of 2.5 mg, 5 mg, and 10 mg. The drug falls in the ant-diabetic segment.

The estimated sales in 2014 for Glipizide ER tablets is USD 90.1 million, as per IMS.

The group now has 97 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com

CIN-1 242302 140050T 60024-4